Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma

Journal of Urology

Volumn 177, Issue 3, 2007, Pages 1157-1162

  Komohara, Yoshihiro ^a   Harada, Mamoru ^a   Arima, Yoshimi ^a   Suekane, Shigetaka ^a   Noguchi, Masanori ^a   Yamada, Akira ^a,b   Itoh, Kyogo ^a,b   Matsuoka, Kei ^a  

^a KURUME UNIVERSITY   (Japan)

^b Center of the 21st Century Center   (Japan)

Author keywords

cancer vaccines; carcinoma; cytotoxic; kidney; renal cell; T lymphocytes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA A24 ANTIGEN; HLA ANTIGEN CLASS 1; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 3;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, RENAL CELL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; P-GLYCOPROTEINS; RECEPTOR, ERBB-2; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS;

EID: 33846817515     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.10.035     Document Type: Article

References (20)

1. Yagoda A., Abi-Rached B., and Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-93. Semin Oncol 22 (1995) 42
2. Negrier S., Escudier B., Lassest C., Douillard J.Y., Savury J., Chevreau C., et al. Recombinant human interleukin-2, recombinant human interferon alpha-2α, or both in metastatic renal cell carcinoma. New Engl J Med 338 (1998) 1272
3. Rosenberg S.A., Lotze M.T., Yang J.C., Topalian S.L., Chang A.E., Schwartzentruber D.J., et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85 (1993) 622
4. Brandle D., Brasseur F., Weynants P., Boon T., and VandenEynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 183 (1996) 2501
5. Gaudin C., Kremer F., Angevin E., Scott V., and Triebel F. A hsp 70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 162 (1999) 1730
6. Gaugler B., Brouwenstijn N., Vantomme V., Szikora J.P., VanderSpek C.W., Patard J.J., et al. A new gene coding for an antigen recognized by autologous cytotoxic T lymphocytes on a human renal carcinoma. Immunogenetics 44 (1996) 323
7. Ronsin C., Chung-Scott V., Poullion I., Aknouche N., Gaudin C., and Triebel F.A. non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol 163 (1999) 483
8. Vissers J.L., DeVries I.J., Schreurs M.W., Engelen L.P., Oosterwijk E., Figdor C.G., et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59 (1999) 5554
9. Hanada K., Perry-Lalley D.M., Ohnmacht G.A., Bettinotti M.P., and Yang J.C. Induction of fibroblast growth factor-5 as an overexpressed antigen in multipe human adenocarcinomas. Cancer Res 61 (2001) 5511
10. Kawagoe N., Shintaku I., Yutani S., Etoh H., Matsuoka K., Noda S., et al. Expression of the SART3 tumor rejection antigen in renal cell carcinoma. J Urol 164 (2000) 2090
11. Hida N., Maeda Y., Katagiri K., Takasu H., Harada M., and Itoh K. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51 (2002) 219
12. Yamada A., Kawano K., Koga M., Matsumoto T., and Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 61 (2001) 6459
13. + prostate cancer patients. Prostate 60 (2004) 273
14. Azuma K., Shichijo S., Shomura H., Matsueda S., Fujii T., and Itoh K. Identification of HER2/neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients. Breast Cancer Res Treat 86 (2004) 19
15. Sacrdino A., Alves P., Gross D.A., Tourdot S., Graff-Dubois S., Angevin E., et al. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol 31 (2001) 3261
16. Tsai Y.S., Tzai T.S., Chow N.H., and Wu C.L. Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract. Urology 66 (2005) 1197
17. Kool M., deHaas M., Scheffer G.L., Scheper R.J., vanEijk M.J., Juijin J.A., et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57 (1997) 3537
18. Raaphorst F.M., Otte A.P., vanKemenade F.J., Blokzijl T., Fieret E., Hammer K.M., et al. Distinct BMI-1 and EZH2 expression patterns in thynocytes and mature T cells suggest a role for polycomb genes in human T cell differentiation. J Immunol 166 (2001) 5925
19. Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A., et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20 (2002) 2624
20. + T cells from a patient with renal cell carcinoma recognize diverse shared antigens. Int J Cancer 115 (2005) 752